- Conditions
- Arthroplasty, Replacement, Shoulder
- Interventions
- Reverse Total Shoulder
- Device
- Lead sponsor
- DePuy Orthopaedics
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 168 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 15
- States / cities
- Atlantis, Florida • Waltham, Massachusetts • Grand Rapids, Michigan + 12 more
Institution Directory
Clinical trials at Huntsman Cancer Institute (University of Utah)
Sites in Salt Lake City, UT
Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
1140
Shown on this page
12
Current sort
Recently updated
Campus scope
Huntsman Cancer Institute (University of Utah), Salt Lake City, UT
Additional filters apply within this campus.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 373–384 of 1,140 matching trials with a site at Huntsman Cancer Institute (University of Utah), Salt Lake City, UT.
Live ClinicalTrials.gov results.
Live official records
Sleep Harmonization Via Bundled Team-Based Interventions in the ICU
NCT07840560
Site status not listed — check the official record
- Conditions
- Sleep Deprivation, Critical Illness, Sleep-Wake Disorders, Bundle Care, Implementation Science, Delirium
- Interventions
- Nighttime noise & light reduction, Clustering patient-care interactions, Non-pharmacologic sleep aids, Daytime light exposure, Encourage out-of-bed activity, Medication management to support nighttime sleep
- Behavioral · Other
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 62,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 7
- States / cities
- La Jolla, California • San Francisco, California • Orlando, Florida + 4 more
A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC
NCT05884398
Site status not listed — check the official record
- Conditions
- Metastatic Castrate-sensitive Prostate Cancer
- Interventions
- Apalutamide, Androgen-deprivation Therapy (ADT)
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 420 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 46
- States / cities
- Homewood, Alabama • Tucson, Arizona • Little Rock, Arkansas + 37 more
A Phase 1/2/3 Study of UX701 Gene Therapy in Adults With Wilson Disease
NCT04884815
Site status not listed — check the official record
- Conditions
- Wilson Disease
- Interventions
- UX701, Standard of Care (SOC)
- Genetic · Drug
- Lead sponsor
- Ultragenyx Pharmaceutical Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2034
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Redwood City, California • Sacramento, California + 9 more
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
NCT07276399
Status at this site: Recruiting
- Conditions
- Squamous Cell Carcinoma of Head and Neck
- Interventions
- Amivantamab, Pembrolizumab, Carboplatin, 5-Flurouracil, Cisplatin
- Biological · Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 49
- States / cities
- Chandler, Arizona • Tucson, Arizona • Fullerton, California + 43 more
Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial
NCT05327010
Site status not listed — check the official record
- Conditions
- Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
- Interventions
- BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection, Diagnostic Imaging Testing, Talazoparib
- Drug · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 35
- States / cities
- Duarte, California • Irvine, California • La Jolla, California + 28 more
- Conditions
- Chronic Obstructive Pulmonary Disease, Pulmonary Artery Hypertension, Heart Failure, Hypertension
- Interventions
- Maximum Exercise Tests, BH4, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid and L-Ascorbate, BQ-123, Fexofenadine, Ranitidine, Angiotensin-II, Valsartan, Acetylcholine, Sodium Nitroprusside, Angiotensin-II, Norepinephrine, Phentolamine, BQ-123, MitoQ, BH4
- Other · Drug
- Lead sponsor
- D. Walter Wray
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 420 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2030
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
NCT07258511
Status at this site: Recruiting
- Conditions
- Multiple Myeloma
- Interventions
- JNJ-79635322, Teclistamab
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 42
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Duarte, California + 32 more
Postural Motor Activation Deficits After mTBI; Translating Laboratory Findings to Clinical Care
NCT07549529
Status at this site: Recruiting
- Conditions
- Mild Traumatic Brain Injury (mTBI), Concussion, Mild Traumatic Brain Injury
- Interventions
- Motor Activation Physical Therapy for mTBI, Standard of Care Physical Therapy for mTBI
- Other
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 2
- States / cities
- Portland, Oregon • Salt Lake City, Utah
Safety, PK/PD, and Exploratory Efficacy Study of AMT-191 in Classic Fabry Disease
NCT06270316
Status at this site: Recruiting
- Conditions
- Fabry Disease
- Interventions
- AMT-191
- Drug
- Lead sponsor
- UniQure Biopharma B.V.
- Industry
- Eligibility
- 18 Years to 65 Years · Male only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Los Angeles, California • Atlanta, Georgia + 7 more
Mosunetuzumab in Combination With Pirtobrutinib in Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia (MPOWER)
NCT07548450
Site status not listed — check the official record
- Conditions
- Waldenstrom Macroglobulinemia
- Interventions
- Pirtobrutinib, Mosunetuzumab
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2035
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
The RADIANCE II Pivotal Study: A Study of the ReCor Medical Paradise System in Stage II Hypertension
NCT03614260
Site status not listed — check the official record
- Conditions
- Hypertension, Vascular Diseases, Cardiovascular Diseases
- Interventions
- Paradise Renal Denervation System, Renal Angiogram
- Device · Procedure
- Lead sponsor
- ReCor Medical, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 224 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2029
- U.S. locations
- 28
- States / cities
- Birmingham, Alabama • Los Angeles, California • Bridgeport, Connecticut + 24 more
About this Huntsman Cancer Institute (University of Utah) institution page
- What this page lists
- ClinicalTrials.gov records that list Huntsman Cancer Institute (University of Utah) in Salt Lake City, UT as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
- Site status
- A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
- Where the data comes from
- Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
- What this page does not do
- No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.
Related: all institution pages, browse by condition, or browse by U.S. city.